Venable Fitzpatrick successfully defended the validity of a compound patent covering Sanofi’s Jevtana (cabazitaxel) chemotherapy product before the Federal Circuit. Venable Fitzpatrick also succeeded in vacating an adverse judgment to Sanofi regarding a second patent that covers a method of treatment for Jevtana, because the district court lacked subject matter jurisdiction. Jevtana is used for the treatment of advanced prostate cancer where other therapies have failed.
William E. Solander, Daniel J. Minion, Dominick A. Conde, Melinda R. Roberts, Whitney L. Meier, Katherine E. Adams, and Nicholas Marcello represented Sanofi.